Varex Imaging Corporation

NasdaqGS:VREX Stock Report

Market Cap: US$733.6m

Varex Imaging Past Earnings Performance

Past criteria checks 4/6

Varex Imaging hat die Erträge mit einer durchschnittlichen jährlichen Rate von 22.4% gesteigert, während die Branche Medical Equipment die Erträge growing mit 9.1% jährlich steigerte. Die Einnahmen sind growing mit einer durchschnittlichen Rate von 3.2% pro Jahr gestiegen. Varex Imaging Die Eigenkapitalrendite des Unternehmens beträgt 8.4%, und die Nettomargen liegen bei 5.4%.

Key information

32.7%

Earnings growth rate

31.9%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate3.4%
Return on equity7.7%
Net Margin5.1%
Last Earnings Update29 Dec 2023

Recent past performance updates

Recent updates

Varex Imaging Corporation: The Picture Is Cloudy After Quarterly Results

Feb 07

We Like These Underlying Return On Capital Trends At Varex Imaging (NASDAQ:VREX)

Dec 14
We Like These Underlying Return On Capital Trends At Varex Imaging (NASDAQ:VREX)

Is Varex Imaging (NASDAQ:VREX) A Risky Investment?

Nov 05
Is Varex Imaging (NASDAQ:VREX) A Risky Investment?

Is There Now An Opportunity In Varex Imaging Corporation (NASDAQ:VREX)?

Oct 29
Is There Now An Opportunity In Varex Imaging Corporation (NASDAQ:VREX)?

Varex Imaging (NASDAQ:VREX) Hasn't Managed To Accelerate Its Returns

Sep 27
Varex Imaging (NASDAQ:VREX) Hasn't Managed To Accelerate Its Returns

What Is Varex Imaging Corporation's (NASDAQ:VREX) Share Price Doing?

Jul 21
What Is Varex Imaging Corporation's (NASDAQ:VREX) Share Price Doing?

These 4 Measures Indicate That Varex Imaging (NASDAQ:VREX) Is Using Debt Reasonably Well

Jun 15
These 4 Measures Indicate That Varex Imaging (NASDAQ:VREX) Is Using Debt Reasonably Well

Is It Too Late To Consider Buying Varex Imaging Corporation (NASDAQ:VREX)?

Mar 25
Is It Too Late To Consider Buying Varex Imaging Corporation (NASDAQ:VREX)?

Varex Imaging Corporation's (NASDAQ:VREX) CEO Might Not Expect Shareholders To Be So Generous This Year

Feb 04
Varex Imaging Corporation's (NASDAQ:VREX) CEO Might Not Expect Shareholders To Be So Generous This Year

Is Varex Imaging (NASDAQ:VREX) A Risky Investment?

Jan 31
Is Varex Imaging (NASDAQ:VREX) A Risky Investment?

Returns On Capital At Varex Imaging (NASDAQ:VREX) Paint A Concerning Picture

Dec 22
Returns On Capital At Varex Imaging (NASDAQ:VREX) Paint A Concerning Picture

What Does Varex Imaging Corporation's (NASDAQ:VREX) Share Price Indicate?

Nov 08
What Does Varex Imaging Corporation's (NASDAQ:VREX) Share Price Indicate?

Varex Imaging (NASDAQ:VREX) Has A Pretty Healthy Balance Sheet

Oct 11
Varex Imaging (NASDAQ:VREX) Has A Pretty Healthy Balance Sheet

Investors Could Be Concerned With Varex Imaging's (NASDAQ:VREX) Returns On Capital

Sep 01
Investors Could Be Concerned With Varex Imaging's (NASDAQ:VREX) Returns On Capital

Varex Imaging Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Aug 06
Varex Imaging Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Varex Imaging: Low-Growth X-Ray Imaging Component Provider Offers Stable Upside

Jun 20

What Is Varex Imaging Corporation's (NASDAQ:VREX) Share Price Doing?

Jun 07
What Is Varex Imaging Corporation's (NASDAQ:VREX) Share Price Doing?

Varex Imaging (NASDAQ:VREX) Is Making Moderate Use Of Debt

May 11
Varex Imaging (NASDAQ:VREX) Is Making Moderate Use Of Debt

Varex Imaging Corporation 2021 Q2 - Results - Earnings Call Presentation

May 06

Don't Ignore The Fact That This Insider Just Sold Some Shares In Varex Imaging Corporation (NASDAQ:VREX)

Mar 05
Don't Ignore The Fact That This Insider Just Sold Some Shares In Varex Imaging Corporation (NASDAQ:VREX)

Varex Imaging Corporation 2021 Q1 - Results - Earnings Call Presentation

Feb 05

Does Varex Imaging (NASDAQ:VREX) Have A Healthy Balance Sheet?

Jan 22
Does Varex Imaging (NASDAQ:VREX) Have A Healthy Balance Sheet?

Revenue & Expenses Breakdown
Beta

How Varex Imaging makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:VREX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
29 Dec 238784513185
29 Sep 238934812885
30 Jun 238972912883
31 Mar 238802912683
30 Dec 228663211679
30 Sep 228593011777
01 Jul 228542611675
01 Apr 228513011574
31 Dec 218402512273
01 Oct 218181712572
02 Jul 21762-1812771
02 Apr 21722-5812971
01 Jan 21715-6313374
02 Oct 20738-5813379
03 Jul 20771-2313181
03 Apr 20796413183
03 Jan 207951112681
27 Sep 197811612278
28 Jun 19783711679
29 Mar 197781311779
28 Dec 187831911982
28 Sep 187732812383
29 Jun 187844211684
30 Mar 187634911081
29 Dec 17717529974
29 Sep 176985210367
30 Jun 17655599659
31 Mar 17636669056
30 Dec 16631669154
30 Sep 16620698654
01 Jul 16608628055
02 Oct 15632807350
26 Sep 146851106340
27 Sep 136701106236

Qualität der Erträge: VREX hat eine große einmalige loss von $16.4M, die sich auf die Finanzergebnisse der letzten 12 Monate auf 29th September, 2023 auswirkt.

Wachsende Gewinnspanne: VREXDie aktuellen Gewinnspannen (5.4%) sind höher als im letzten Jahr (3.5%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Ergebnisentwicklung: VREXIn den letzten 5 Jahren sind die Einnahmen von 22.4% pro Jahr erheblich gestiegen.

Beschleunigtes Wachstum: VREXDas Gewinnwachstum des Unternehmens im letzten Jahr (59.3%) übertrifft seinen 5-Jahres-Durchschnitt (22.4% pro Jahr).

Erträge im Vergleich zur Industrie: VREX Das Gewinnwachstum im vergangenen Jahr (59.3%) übertraf das der Branche Medical Equipment 3.7% .


Return on Equity

Hohe Eigenkapitalrendite: VREXDie Eigenkapitalrendite des Unternehmens (8.4%) wird als niedrig angesehen.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.